HepaLife Technologies Inc. (OTC:HPLF) is now Alliqua Inc.

The company’s product offering has transformed from a largely liver-focused health technologies to drug delivery and wound care and the new branding is designed to reflect that change, according to HepaLife.

"As demonstrated by our recent announcements, such as the 510(k) submission for our silver-based antimicrobial wound care dressing, we are committed to becoming a leading distributor of innovative product solutions in our respective healthcare verticals. With various new products in the pipeline, we look forward to keeping our loyal shareholders and prospective investors apprised of our developments into 2011 and beyond," HepaLife president Richard Rosenblum said in prepared remarks.

HepaLife in November formed subsidiary Alliqua BioMedical Inc. to launch its existing transdermal drug delivery and wound care technologies into new markets.

The New York City-based company in May acquired AquaMed Technologies Inc., which makes hydrogels used for transdermal drug delivery, in an all-stock deal valued at about $16 million. The company said AquaMed’s 16,500-square-foot, cGMP-compliant, Food & Drug Administration-registered facility is “crucial in helping Alliqua meet its strategic growth objectives.” As part of the new firm’s launch, HepaLife named AquaMed CEO Matt Harriton as Alliqua BioMedical’s chief executive.

HepaLife’s ticker symbol will remain the same until independent securities regulator FINRA makes an appropriate change.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW